[What's new in the management of endometrial cancer? Update on the new European recommendations for 2021].

Quelles nouveautés pour la prise en charge du cancer de l’endomètre ? Le point sur les recommandations européennes de 2021.
Analyse moléculaire Cancer endomètre Endometrial cancer European Européennes Ganglion sentinelle Guidelines Indocyanine Molecular analysis Recommandations Sentinel lymph node

Journal

Gynecologie, obstetrique, fertilite & senologie
ISSN: 2468-7189
Titre abrégé: Gynecol Obstet Fertil Senol
Pays: France
ID NLM: 101693805

Informations de publication

Date de publication:
09 2021
Historique:
received: 19 02 2021
pubmed: 25 3 2021
medline: 25 11 2021
entrez: 24 3 2021
Statut: ppublish

Résumé

The new European guidelines for the management of patients with endometrial cancer were published in early 2021. These recommendations are joint to the three European Learned Societies of Gynecologic Oncology (ESGO), Radiation Therapy and Oncology (ESTRO) and Anatomical Pathology (ESP). On behalf of the French Society of Gynecologic Oncology (SFOG), we wish to bring to the knowledge of the French-speaking readership the main measures for the management of patients which represent an advance compared to the 2016 recommendations. The new European recommendations for the management of patients with endometrial cancer emphasize the generalization of micro-satellite instability (MSI) or immunohistochemical analysis of MMR system proteins for all patients. Also, the classification into 4 prognostic risk groups integrates data from molecular analysis (p53, MSI, POLE) to guide initial surgical management as well as adjuvant treatment modalities. The indocyanine green sentinel node procedure has also become the reference technique for FIGO I and II lymph node staging regardless of histological type. It should be remembered that management should be provided in a specialized institution by a team specialized in the management of gynecological cancers, particularly for high-risk and/or advanced cancer patients.

Identifiants

pubmed: 33757927
pii: S2468-7189(21)00054-4
doi: 10.1016/j.gofs.2021.03.005
pii:
doi:

Substances chimiques

Indocyanine Green IX6J1063HV

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

691-697

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Auteurs

H Azaïs (H)

Department of Gynecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, France.

L Lecointre (L)

Department of Obstetrics and Gynecology, Strasbourg University Hospital, France; I-Cube UMR 7357 - Laboratoire des Sciences de L'ingénieur, de L'informatique et de L'imagerie. Université de Strasbourg, Strasbourg, France.

G Canlorbe (G)

Assistance Publique des Hôpitaux de Paris (AP-HP), Department of Gynecological and Breast Surgery and Oncology, Pitié-Salpêtrière University Hospital, 75013 Paris, France; Sorbonne University, Inserm UMR_S_938, Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France. Electronic address: geoffroy.canlorbe@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH